Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.